LeonaBio, Inc. SEC filings document the company’s status as a Delaware clinical-stage biopharmaceutical issuer listed on The Nasdaq Capital Market under the LONA ticker. Its 8-K reports furnish financial results, business updates, Regulation FD disclosures, board matters, and material events tied to its product candidates and corporate development activity.
Registration statement amendments cover delayed or continuous securities offerings, while amended material-event filings document the completed Sermonix license transaction, related securities issuance, and SEC accounting disclosures under Regulation S-X. The filing record also reflects the company’s transition from Athira Pharma to LeonaBio and the capital-structure disclosures associated with its common stock and warrants.
LeonaBio, Inc. director Peter B. Silverman filed an initial Form 3 as a reporting person for the company. The filing lists him as a director but shows no reported purchases, sales, or other transactions in LeonaBio securities, and no derivative holdings in this snapshot.
LeonaBio, Inc. filed an initial Form 3 identifying Natalie C. Holles as a director and reporting person for the company’s securities. The filing does not report any transactions or holdings, serving mainly to establish her status under insider reporting rules.
LeonaBio, Inc. director Callori Fred filed an initial Form 3 to report insider status with the company. The filing lists no stock purchases, sales, option exercises, gifts, or other transactions, indicating this is a baseline ownership disclosure rather than a record of trading activity.
Perceptive Advisors and affiliates report owning 1,882,370 shares of LeonaBio common stock, representing 19.99% of the class. The stake includes 1,552,614 shares, or 16.5%, held by Perceptive Life Sciences Master Fund, Ltd. and 352,804 shares, or 3.7%, held by Perceptive Xontogeny Venture Fund II.
The ownership percentages are based on 9,393,514 shares of common stock outstanding and give effect to warrants allowing purchase of 23,048 additional shares subject to limits. A Beneficial Ownership Limitation prevents exercises that would take the group above 19.99%. On May 5, 2026, Fred Callori, a Partner and Managing Director at Perceptive Advisors, was appointed to LeonaBio’s board of directors. The filers report no transactions in the company’s stock during the prior sixty days.
LeonaBio, Inc., a clinical-stage biopharma company, reported a net loss of $32.9M for the quarter ended March 31, 2026, compared with $9.1M a year earlier. The larger loss was driven by higher research and development spending and a $16.3M non-cash loss from remeasuring the Sermonix pre-funded warrant before it was reclassified to equity.
Research and development expenses rose to $11.3M, mainly reflecting investment in lasofoxifene and ATH-1105, while general and administrative costs increased to $6.9M. Cash, cash equivalents and investments totaled $67.7M, and management believes this will fund operations for at least 12 months based on the current plan.
LeonaBio, Inc. reported first quarter 2026 results and highlighted progress in its oncology and neurodegeneration pipeline. The company is running the Phase 3 ELAINE‑3 trial of lasofoxifene in ER‑positive, HER2‑negative, ESR1‑mutated metastatic breast cancer, plans to increase enrollment to up to 600 patients, expects to complete enrollment in 4Q 2026 and to report topline data in the second half of 2027.
ATH‑1105, an oral, brain‑penetrant candidate for ALS, showed favorable safety, pharmacokinetics and CNS penetration in a Phase 1 trial, and LeonaBio aims to start a Phase 2 proof‑of‑concept study in ALS patients in the second half of 2026. Cash, cash equivalents and investments were $67.7 million as of March 31, 2026, compared with $88.3 million as of December 31, 2025, reflecting higher operating spend.
Research and development expenses rose to $11.3 million for the quarter from $4.3 million a year earlier, mainly from the ELAINE‑3 trial, while general and administrative expenses increased to $6.9 million from $5.2 million. Net loss widened to $32.9 million, or $1.73 per share, from $9.1 million, or $2.34 per share, driven in part by a non‑cash $16.3 million change in fair value of a Sermonix pre‑funded warrant.
LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock, with an exercise price of $9.54 per share and expiration on April 8, 2036. These options were granted at no upfront cost as compensation, not through an open-market purchase.
According to the grant terms, the 28,000 option shares are scheduled to vest in equal monthly installments over 24 months from the grant date, as long as Panzara continues to serve as a “Service Provider” under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds 28,000 derivative securities tied to LeonaBio common stock.
LeonaBio, Inc. reported that its Chief Scientific Officer, Kevin Church, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was received as a compensation-related grant, not an open-market purchase or sale. According to the grant terms, the options are scheduled to vest monthly over 48 months, as long as Church continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Grant Pickering received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. This is a compensation-related award, not an open-market trade.
The filing shows Pickering holding 28,000 options after the transaction. According to the footnote, the options vest monthly over 24 months from the grant date, contingent on continued service as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Romano Kelly A received a grant of stock options covering 28,000 shares of common stock on April 9, 2026. The options carry an exercise price of $9.54 per share and expire on April 8, 2036. According to the award terms, the 28,000 underlying shares are scheduled to vest in equal monthly installments over 24 months, contingent on Kelly continuing as a Service Provider under LeonaBio's 2026 Equity Incentive Plan.